文献速递中毒与环境急症消化、代谢与肾脏急症

金雀花碱用于戒烟:ORCA 3期重复随机临床试验

Cytisinicline for Smoking Cessation: The ORCA Phase 3 Replication Randomized Clinical Trial.
PubMed 文献 · JAMA Intern Med · 2025-01-01
一句话结论在每日吸烟≥10支的成人中,金雀花碱3 mg每日3次治疗6或12周均显著提高一氧化碳验证的持续戒烟率,且耐受性良好。

ORCA-3是在美国20个临床试验点开展的3组双盲、安慰剂对照3期重复随机临床试验,纳入792名每日吸烟≥10支且有意戒烟的成人,按1:1:1随机分为金雀花碱3 mg每日3次12周组、金雀花碱3 mg每日3次6周后安慰剂6周组、安慰剂每日3次12周组,均接受行为支持,随访24周。主要终点为治疗最后4周经一氧化碳<10 ppm验证的持续戒烟率:6周治疗组金雀花碱14.8% vs 安慰剂6.0%(OR 2.9,95%CI 1.5-5.6,P<.001);12周治疗组金雀花碱30.3% vs 安慰剂9.4%(OR 4.4,95%CI 2.6-7.3,P<.001)。次要终点持续戒烟率至24周在两组均高于安慰剂,第6周渴求评分下降幅度金雀花碱组大于安慰剂组,无治疗相关严重不良事件。

要点

  • 12周金雀花碱3 mg每日3次组第9-12周持续戒烟率30.3%,显著高于安慰剂组9.4%(OR 4.4,95%CI 2.6-7.3,P<.001)。
  • 6周金雀花碱3 mg每日3次组第3-6周持续戒烟率14.8%,显著高于安慰剂组6.0%(OR 2.9,95%CI 1.5-5.6,P<.001)。
  • 持续戒烟率至24周:6周治疗组金雀花碱6.8% vs 安慰剂1.1%;12周治疗组金雀花碱20.5% vs 安慰剂4.2%。
  • 第6周渴求评分下降金雀花碱组-15.2分(95%CI -16.4至-14.0)大于安慰剂组-12.0分(95%CI -13.5至-10.5),P<.001。
  • 金雀花碱耐受性良好,无治疗相关严重不良事件。

适用人群与场景

  • 美国20个临床试验点纳入的每日吸烟≥10支且有意戒烟的成人;平均(SD)年龄52.0(11.8)岁,女性439例(55.4%),平均(SD)每日吸烟量20.4(7.5)支。

诊断标准与关键阈值

  • 主要终点为治疗最后4周经一氧化碳<10 ppm生化验证的持续戒烟:6周治疗组评估第3-6周,12周治疗组评估第9-12周。
  • 次要终点为治疗结束至24周的持续戒烟:6周治疗组评估第3-24周,12周治疗组评估第9-24周。

处置流程与药物剂量

  • 金雀花碱3 mg每日3次口服共12周,联合行为支持。
  • 金雀花碱3 mg每日3次口服共6周,随后安慰剂每日3次共6周,联合行为支持。
  • 安慰剂每日3次口服共12周,联合行为支持。

研究设计与关键结果

  • 3组双盲、安慰剂对照3期重复随机临床试验(ORCA-3),在美国20个临床试验点于2022年1月至2023年3月开展,792例随机(1:1:1),628例(79.3%)完成试验。
  • 6周治疗第3-6周持续戒烟:金雀花碱组39例(14.8%)vs 安慰剂组16例(6.0%),OR 2.9(95%CI 1.5-5.6),P<.001。
  • 12周治疗第9-12周持续戒烟:金雀花碱组80例(30.3%)vs 安慰剂组25例(9.4%),OR 4.4(95%CI 2.6-7.3),P<.001。
  • 6周治疗第3-24周持续戒烟率:金雀花碱组6.8% vs 安慰剂组1.1%。
  • 12周治疗第9-24周持续戒烟率:金雀花碱组20.5% vs 安慰剂组4.2%。
  • 第6周渴求评分下降:金雀花碱组-15.2分(95%CI -16.4至-14.0)vs 安慰剂组-12.0分(95%CI -13.5至-10.5),P<.001。
  • 金雀花碱耐受性良好,无治疗相关严重不良事件。

证据类型、等级与局限

  • 证据类型:3期重复随机、双盲、安慰剂对照临床试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,ORCA 3期试验结果重申金雀花碱6周和12周治疗对戒烟的疗效和耐受性,获益持续至24周。
  • 作者认为,作为作用机制,金雀花碱减轻了尼古丁渴求。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: New smoking cessation medication options are needed. Cytisinicline, a partial agonist at α4β2 nicotinic acetylcholine receptors, has demonstrated smoking cessation efficacy in 1 US trial. Additional evidence is needed.

OBJECTIVE: To reproduce the findings of the efficacy and tolerability of cytisinicline compared with placebo for smoking cessation and to test its effect on nicotine craving as a mechanism of action.

DESIGN, SETTINGS, AND PARTICIPANTS: This was a 3-group double-blind, placebo-controlled phase 3 replication randomized clinical trial (ORCA-3) conducted at 20 clinical trial sites in the US from January 2022 to March 2023. It compared 6 and 12 weeks of a novel cytisinicline regimen to placebo among adults who smoked 10 or more cigarettes daily and sought to quit. Participants were randomized (1:1:1) to 3-mg cytisinicline 3 times daily for 12 weeks; 3-mg cytisinicline 3 times daily for 6 weeks followed by placebo for 6 weeks; or placebo 3 times daily for 12 weeks. The follow-up period was 24 weeks, and all groups received behavioral support. Data analyses were performed from May 3, 2023, to March 20, 2024.

INTERVENTIONS: Cytisinicline, 3 mg, 3 times daily for 12 weeks; cytisinicline, 3 mg, 3 times daily for 6 weeks followed by placebo for 6 weeks; or placebo 3 times daily for 12 weeks.

MAIN OUTCOMES AND MEASURES: Biochemically verified (carbon monoxide <10 ppm) continuous smoking abstinence during the last 4 weeks of 6- and 12-week treatments (primary outcome) and from end of treatment to 24 weeks (secondary outcome); Questionnaire of Smoking Urges; incidence of adverse events.

RESULTS: Of 792 participants randomized (mean [SD] age, 52.0 [11.8] years; 439 [55.4%] female; mean [SD] cigarettes/d, 20.4 [7.5]), 628 (79.3%) completed the trial. Primary and secondary outcomes were significantly higher for both cytisinicline groups vs placebo. For 6-week treatment, 39 cytisinicline participants (14.8%) vs 16 placebo participants (6.0%) were abstinent during weeks 3 to 6 (odds ratio [OR], 2.9; 95% CI, 1.5-5.6; P < .001). For 12-week treatment, 80 cytisinicline participants (30.3%) vs 25 placebo participants (9.4%) were abstinent during weeks 9 to 12 (OR, 4.4; 95% CI, 2.6-7.3; P < .001). Continuous abstinence rates for the 6-week treatment were 6.8% (cytisinicline) vs 1.1% (placebo) from weeks 3 to 24 . Continuous abstinence rates for the 12-week treatment were 20.5% (cytisinicline) vs 4.2% (placebo) for weeks 9 to 24. Reduction in craving at week 6 was greater for cytisinicline than placebo (-15.2 points [95% CI, -16.4 to -14.0] vs -12.0 points [95% CI, -13.5 to -10.5]; P < .001). Cytisinicline was well tolerated with no treatment-related serious adverse events.

CONCLUSIONS AND RELEVANCE: The findings of the ORCA phase 3 trial reaffirms the efficacy and tolerability of cytisinicline at both 6- and 12-week treatment for smoking cessation, with benefits extending through 24 weeks. As a mechanism of effect, cytisinicline mitigated nicotine craving.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05206370.

来源:JAMA Intern Med,查看原文。版权归原作者所有。

参考来源

  1. Rigotti NA, Benowitz NL, Prochaska JJ, et al. Cytisinicline for Smoking Cessation: The ORCA Phase 3 Replication Randomized Clinical Trial. JAMA Intern Med. 2025. PMID: 40257755. doi:10.1001/jamainternmed.2025.0628

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。